Human corticotropin-releasing hormone improves overnight FEV1 in nocturnal asthma

George Georges, Monica Kraft, Elcio O. Vianna, Richard J. Martin

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Corticotropin-releasing hormone (CRH) exhibits anti-inflammatory properties independent of its effect on adrenal function. We investigated the safety and effect of CRH in nocturnal asthma, a disease where inflammation is prominent. Five subjects underwent an overnight infusion of placebo on the first night, CRH at a 2.5 μg/kg/hr on the second night, and three subjects received CRH at 4.0 μg/kg/hr on the third night. A significant improvement occurred in overnight change in forced expiratory volume at 1 sec. % (ΔFEV1) with CRH (+17.4 ± 9.1%) as opposed to placebo (-25.9 ± 7.1%), p = 0.024. CRH was well tolerated. Further research with CRH may clarify the pathophysiology of nocturnal asthma.

Original languageEnglish (US)
Pages (from-to)261-265
Number of pages5
JournalJournal of Asthma
Issue number3
StatePublished - 1998


  • Corticotropin-releasing hormone
  • Inflammation
  • Nocturnal asthma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Human corticotropin-releasing hormone improves overnight FEV1 in nocturnal asthma'. Together they form a unique fingerprint.

Cite this